Some very interesting news from Boston already. Endpoints have published an article about the very good results achieved by AbbVie and Calibr with their ‘switchable’ CAR-T program. They have announced their results of a clinical trial stated "Out of nine patients, six went into complete remission, and one more had a partial response. The first patient who had a complete response saw their disease return after nearly one year". The article also featured Penn's Daniel Powell, who it says "...published on the approach in 2012 and licensed his own antibody-CAR-T system to Prescient Therapeutics." Full article here endpts dot com/four-years-in-the-making-abbvie-and-calibr-provide-first-look-into-switchable-car-t-program/
So we look set for a enthusiastic response to Rebecca's presentation and the CellPryme announcement.
